Natalizumab versus Interferon β-1b to prevent CDMS in patients with CIS and poor prognostic factors: research protocol

Heredia Carqués, Cristina
About 85% of multiple sclerosis (MS) cases start as clinically isolated syndrome (CIS). When patients present with a CIS, clinicians face with many questions, most of them related with prognosis and treatment. Thereby, patients with CIS have been focus of research. Several studies have demonstrated a relationship between positive IgM lipidspecific oligoclonal band pattern in CSF and higher lesion load on MRI brain scan, higher number of relapses and greater disability, even at the first stages of the disease. On the other hand, no studies have used this previous evidence to treat with more aggressive disease modifying therapy in initial stages of disease course to prevent the earlier axonal damage. The aim of this study is to assess the most effective approved treatment for MS and current therapy for CIS patients presenting high risk to develop CDMS and with biomarkers of poor prognosis. Among this group of patients any disease activity will eventually lead to disability. Therefore, the earlier the treatment is initiated, the more effective to prevent disability will be. It is considered that “time lost is brain lost” and since once damage is established, there is no therapy to be regained later on. In this phase III clinical trial, 172 patients will be randomized 1:1 to receive Interferon β-1b or natalizumab over 96 weeks. Time to develop clinical definitive multiple sclerosis (CDMS) will be included as primary endpoint. Other secondary endpoints will include clinical data, magnetic resonance imaging (MRI) measurements and quality of life tests ​
This document is licensed under a Creative Commons:Attribution - Non commercial - No Derivate Works (by-nc-nd) Creative Commons by-nc-nd3.0